Jay Olson
Stock Analyst at Oppenheimer
(3.69)
# 756
Out of 4,963 analysts
241
Total ratings
42.05%
Success rate
9.66%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $44 | $6.99 | +529.47% | 4 | Aug 11, 2025 | |
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $9.85 | +153.81% | 1 | Aug 4, 2025 | |
| ATAI Atai Life Sciences | Initiates: Outperform | $14 | $4.57 | +206.35% | 1 | Jul 29, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $26.57 | -17.20% | 15 | Jun 26, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $8.56 | - | 15 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $30.48 | +113.25% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $2.90 | +2,141.38% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $2.46 | +428.46% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $38.04 | +97.16% | 9 | May 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $5.19 | +304.62% | 2 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $29.28 | +207.38% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $15.62 | +168.89% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $38.50 | -14.29% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $11.42 | +250.26% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.72 | +1,062.79% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $7.78 | +285.60% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $6.89 | +190.28% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $136.36 | +87.00% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $84.84 | -3.35% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $425.06 | -17.66% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.41 | +193.26% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $26.62 | +418.41% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.87 | +327.81% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $287.97 | +31.96% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $138.13 | +58.55% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.67 | +349.44% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.42 | +426.32% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.90 | +1,006.68% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $53.53 | +77.47% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.46 | +622.54% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $42.75 | +75.44% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $3.06 | +194.12% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $9.34 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.62 | +30,764.20% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $8.55 | +145.76% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.67 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.27 | +386.39% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.13 | - | 3 | Jul 11, 2017 |
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $6.99
Upside: +529.47%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $9.85
Upside: +153.81%
Atai Life Sciences
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $4.57
Upside: +206.35%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $26.57
Upside: -17.20%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $8.56
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $30.48
Upside: +113.25%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $2.90
Upside: +2,141.38%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $2.46
Upside: +428.46%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $38.04
Upside: +97.16%
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $5.19
Upside: +304.62%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $29.28
Upside: +207.38%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $15.62
Upside: +168.89%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $38.50
Upside: -14.29%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $11.42
Upside: +250.26%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.72
Upside: +1,062.79%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $7.78
Upside: +285.60%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $6.89
Upside: +190.28%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $136.36
Upside: +87.00%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $84.84
Upside: -3.35%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $425.06
Upside: -17.66%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.41
Upside: +193.26%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $26.62
Upside: +418.41%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.87
Upside: +327.81%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $287.97
Upside: +31.96%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $138.13
Upside: +58.55%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.67
Upside: +349.44%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.42
Upside: +426.32%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.90
Upside: +1,006.68%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $53.53
Upside: +77.47%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $3.46
Upside: +622.54%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $42.75
Upside: +75.44%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $3.06
Upside: +194.12%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $9.34
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.62
Upside: +30,764.20%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $8.55
Upside: +145.76%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.67
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.27
Upside: +386.39%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.13
Upside: -